Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
The DOI matches its Crossref record; 186 of the 186 references it cites were found in a registry or an index.
Abstract
Early prediction of clearance mechanisms allows for the rapid progression of drug discovery and development programs, and facilitates risk assessment of the pharmacokinetic variability associated with drug interactions and pharmacogenomics. Here we propose a scientific framework--Extended Clearance Classification System (ECCS)--which can be used to predict the predominant clearance mechanism (rate-determining process) based on physicochemical properties and passive membrane permeability. Compounds are classified as: Class 1A--metabolism as primary systemic clearance mechanism (high permeability acids/zwitterions with molecular weight (MW) ≤400 Da), Class 1B--transporter-mediated hepatic uptake as primary systemic clearance mechanism (high permeability acids/zwitterions with MW >400 Da), Class 2--metabolism as primary clearance mechanism (high permeability bases/neutrals), Class 3A--renal clearance (low permeability acids/zwitterions with MW ≤400 Da), Class 3B--transporter mediated hepatic uptake or renal clearance (low permeability acids/zwitterions with MW >400 Da), and Class 4--renal clearance (low permeability bases/neutrals). The performance of the ECCS framework was validated using 307 compounds with single clearance mechanism contributing to ≥70% of systemic clearance. The apparent permeability across clonal cell line of Madin - Darby canine kidney cells, selected for low endogenous efflux transporter expression, with a cut-off of 5 × 10(-6) cm/s was used for permeability classification, and the ionization (at pH7) was assigned based on calculated pKa. The proposed scheme correctly predicted the rate-determining clearance mechanism to be either metabolism, hepatic uptake or renal for ~92% of total compounds. We discuss the general characteristics of each ECCS class, as well as compare and contrast the framework with the biopharmaceutics classification system (BCS) and the biopharmaceutics drug disposition classification system (BDDCS). Collectively, the ECCS framework is valuable in early prediction of clearance mechanism and can aid in choosing the right preclinical tool kit and strategy for optimizing drug exposure and evaluating clinical risk of pharmacokinetic variability caused by drug interactions and pharmacogenomics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the renal side, the organic cation transporter OCT2 (SLC22A2) together with the multidrug and toxin extrusion proteins MATE1 and MATE2-K mediate active secretion of hydrophilic cations; metformin is the archetype, its clearance being governed by OCT2-mediated uptake and MATE-mediated efflux rather than by glomerular filtration alone, so its disposition tracks transporter activity rather than”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [41]
In the citing paper
“P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) govern intestinal absorption, biliary excretion, and central nervous system penetration, and their expression, tissue localization, and substrate affinity differ appreciably between rodents, dogs, non-human primates, and humans; body-weight scaling captures none of this, whereas the Extended Clearance Classification Syst”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [41]
In the citing paper
“The Extended Clearance Classification System (ECCS) provides a useful framework for predicting dominant clearance mechanisms and thereby assessing the likely reliability of allometric scaling for a given compound [41].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [41]
In the citing paper
“The case directly catalyzed contemporary requirements for thorough QT studies and hERG screening, the metabolite-aware DDI evaluations that ECCS classification now anchors [41,43,44], and the broader regulatory expectation that compounds with active metabolites or saturable first-pass pathways be characterized across realistic co-medication scenarios rather than in isolation.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [41]
In the citing paper
“The case is now a canonical example of why ECCS classification, transporter-DDI screening, and post-marketing pharmacoepidemiology must be integrated alongside any allometric or PBPK extrapolation [41,43,44,79].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [41]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.019 · Cited by 3,700
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340 · cited 1×
“disposition, therapeutic efficacy, and toxicity [25].”
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R., & Ball, S. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000794 · Cited by 928
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
(2001) · Drugs and the Pharmaceutical Sciences · doi:10.1201/9780824741969.axh · Cited by 818
Pang, K. S., & Rowland, M. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059688 · Cited by 797 · cited 2×
“of intrinsic metabolic and biliary clearance (PSpd >> CLint,met+CLint,bile) [13]:”
The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 633
BDDCS Applied to Over 900 Drugs
Benet, L. Z., Broccatelli, F., & Oprea, T. I. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9290-9 · Cited by 626
Clinical Pharmacokinetics of Atorvastatin
Lennern??s, H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00005 · Cited by 623
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 576
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
Clinical pharmacokinetics of tyrosine kinase inhibitors
van Erp, N. P., Gelderblom, H., & Guchelaar, H.-J. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.004 · Cited by 503
Transporters and drug therapy: Implications for drug disposition and disease
HO, R., & KIM, R. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.011 · Cited by 502
Lennernaäs, H. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js970332a · Cited by 500
Transporters as a determinant of drug clearance and tissue distribution
Shitara, Y., Horie, T., & Sugiyama, Y. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.12.003 · Cited by 496
Absorption and Drug Development: Solubility, Permeability, and Charge State
Avdeef, A. (2003) · Cited by 482
First-pass metabolism of midazolam by the human intestine*
Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Marsh, C. L., McVicar, J. P., Barr, D., Gillies, B. S., & Thummel, K. E. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90162-9b · Cited by 465
Obach, R. S., Lombardo, F., & Waters, N. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020479 · Cited by 462
Cellular and molecular aspects of drug transport in the kidney
Inui, K.-I., Masuda, S., & Saito, H. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00251.x · Cited by 450
Absorption and Drug Development: Solubility, Permeability, and Charge State
Avdeef, A. (2012) · Wiley eBooks · doi:10.1002/9781118286067 · Cited by 446
Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans
Hirano, M., Maeda, K., Shitara, Y., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068056 · Cited by 443
The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs
Shugarts, S., & Benet, L. Z. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9924-0 · Cited by 438
Custodio, J. M., Wu, C.-Y., & Benet, L. Z. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.043 · Cited by 434
Shitara, Y., Maeda, K., Ikejiri, K., Yoshida, K., Horie, T., & Sugiyama, Y. (2013) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1823 · Cited by 418
Shitara, Y., Hirano, M., Sato, H., & Sugiyama, Y. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068536 · Cited by 407
Clinical Pharmacokinetics of Diclofenac: Therapeutic Insights and Pitfalls
Davies, N. M., & Anderson, K. E. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733030-00003 · Cited by 398
Swift*, B., Pfeifer*, N. D., & Brouwer, K. L. R. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903491881 · Cited by 365
Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin
Kitamura, S., Maeda, K., Wang, Y., & Sugiyama, Y. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021410 · Cited by 361
Applications of CYP450 Testing in the Clinical Setting
Samer, C. F., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0028-5 · Cited by 354
Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y., & Sugiyama, Y. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146647 · Cited by 351
Camenisch, G., Alsenz, J., van de Waterbeemd, H., & Folkers, G. (1998) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(97)10019-7 · Cited by 347
EVALUATION OF DRUG-DRUG INTERACTION IN THE HEPATOBILIARY AND RENAL TRANSPORT OF DRUGS
Shitara, Y., Sato, H., & Sugiyama, Y. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121444 · Cited by 336 · cited 1×
“Tubular secretion facilitates transport of compounds from the plasma into the proximal tubular lumen, which is predominantly controlled by active transporters and is therefore dependent on transporter kinetics, fb, and the blood flow rate [73, 74].”
Gemfibrozil greatly increases plasma concentrations of cerivastatin
Backman, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128469 · Cited by 336
Varma, M. V. S., Obach, R. S., Rotter, C., Miller, H. R., Chang, G., Steyn, S. J., El-Kattan, A., & Troutman, M. D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901371v · Cited by 331
Self-citationLau, Y. Y., Huang, Y., Frassetto, L., & Benet, L. Z. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100038 · Cited by 327
Matsson, P., Pedersen, J. M., Norinder, U., Bergström, C. A. S., & Artursson, P. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9896-0 · Cited by 316
Pharmacogenetics of Warfarin Elimination and Its Clinical Implications
Takahashi, H., & Echizen, H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140080-00003 · Cited by 312
First-pass metabolism of midazolam by the human intestine*
Paine, M. F., Shen, D. D., Kunze, K. L., Perkins, J. D., Marsh, C. L., McVicar, J. P., Barr, D. M., Gillies, B. S., & Thummel, K. E. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90162-9 · Cited by 302
Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300
Effects of renal failure on drug transport and metabolism
Sun, H., Frassetto, L., & Benet, L. Z. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.010 · Cited by 290
Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist
Dingemanse, J., & van Giersbergen, P. L. M. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443150-00003 · Cited by 272
De Buck, S. S., Sinha, V. K., Fenu, L. A., Nijsen, M. J., Mackie, C. E., & Gilissen, R. A. H. J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015644 · Cited by 256
Tang, M., Mukundan, M., Yang, J., Charpentier, N., LeCluyse, E. L., Black, C., Yang, D., Shi, D., & Yan, B. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110577 · Cited by 250
Jones, H. M., Barton, H. A., Lai, Y., Bi, Y.-A., Kimoto, E., Kempshall, S., Tate, S. C., El-Kattan, A., Houston, J. B., Galetin, A., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042994 · Cited by 244
Self-citationInteractions Between Grapefruit Juice and Cardiovascular Drugs
Bailey, D. G., & Dresser, G. K. (2004) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200404050-00002 · Cited by 239
Roffey, S. J., Obach, R. S., Gedge, J. I., & Smith, D. A. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530600952172 · Cited by 239
Recent Advances in Carrier-mediated Hepatic Uptake and Biliary Excretion of Xenobiotics
Yamazaki, M., Suzuki, H., & Sugiyama, Y. (1996) · Pharmaceutical Research · doi:10.1023/a:1016077517241 · Cited by 221
Physicochemical Determinants of Human Renal Clearance
Varma, M. V. S., Feng, B., Obach, R. S., Troutman, M. D., Chupka, J., Miller, H. R., & El-Kattan, A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900403j · Cited by 213
Self-citationJeu, L., Piacenti, F. J., Lyakhovetskiy, A. G., & Fung, H. B. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80126-1 · Cited by 213
Ieiri, I., Higuchi, S., & Sugiyama, Y. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902976854 · Cited by 212
Maeda, K., Ikeda, Y., Fujita, T., Yoshida, K., Azuma, Y., Haruyama, Y., Yamane, N., Kumagai, Y., & Sugiyama, Y. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.142 · Cited by 211
Yamashiro, W., Maeda, K., Hirouchi, M., Adachi, Y., Hu, Z., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008938 · Cited by 202
Interactions of Human Organic Anion Transporters with Diuretics
Hasannejad, H., Takeda, M., Taki, K., Shin, H. J., Babu, E., Jutabha, P., Khamdang, S., Aleboyeh, M., Onozato, M. L., Tojo, A., et al. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.059139 · Cited by 200
Elsby, R., Hilgendorf, C., & Fenner, K. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.163 · Cited by 198
Watanabe, T., Kusuhara, H., Maeda, K., Kanamaru, H., Saito, Y., Hu, Z., & Sugiyama, Y. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.030254 · Cited by 194
Ahlin, G., Karlsson, J., Pedersen, J. M., Gustavsson, L., Larsson, R., Matsson, P., Norinder, U., Bergström, C. A. S., & Artursson, P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8003152 · Cited by 190
Pharmacokinetics of Budesonide (Entocort??? EC) Capsules for Crohn???s Disease
Edsb??cker, S., & Andersson, T. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443120-00003 · Cited by 181
Chu, X.-Y., Bleasby, K., Yabut, J., Cai, X., Chan, G. H., Hafey, M. J., Xu, S., Bergman, A. J., Braun, M. P., Dean, D. C., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.116517 · Cited by 179
Ohno, Y., Hisaka, A., & Suzuki, H. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746080-00005 · Cited by 173
Tahara, H., Kusuhara, H., Endou, H., Koepsell, H., Imaoka, T., Fuse, E., & Sugiyama, Y. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.088104 · Cited by 171
Prueksaritanont, T., Chu, X., Evers, R., Klopfer, S. O., Caro, L., Kothare, P. A., Dempsey, C., Rasmussen, S., Houle, R., Chan, G., et al. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12377 · Cited by 169
Millburn, P., Smith, R. L., & Williams, R. T. (1967) · Biochemical Journal · doi:10.1042/bj1051275 · Cited by 169
Pea, F., & Furlanut, M. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140110-00004 · Cited by 165
Varma, M. V., Gardner, I., Steyn, S. J., Nkansah, P., Rotter, C. J., Whitney-Pickett, C., Zhang, H., Di, L., Cram, M., Fenner, K. S., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp2004912 · Cited by 164
Self-citationVarma, M. V. S., Sateesh, K., & Panchagnula, R. (2005) · Molecular Pharmaceutics · doi:10.1021/mp0499196 · Cited by 161
Self-citationKing, C. (2001) · Toxicological Sciences · doi:10.1093/toxsci/61.1.49 · Cited by 159
MUCK, W., MAI, I., FRITSCHE, L., OCHMANN, K., ROHDE, G., UNGER, S., JOHNE, A., BAUER, S., BUDDE, K., & ROOTS, I. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70104-9 · Cited by 158
Lau, Y. Y., Okochi, H., Huang, Y., & Benet, L. Z. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093088 · Cited by 155
Clinical pharmacokinetics of voriconazole
Levêque, D., Nivoix, Y., Jehl, F., & Herbrecht, R. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.01.003 · Cited by 154
Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo
Soars, M. G., Grime, K., Sproston, J. L., Webborn, P. J. H., & Riley, R. J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014464 · Cited by 153
Renal Transporters for Organic Anions and Organic Cations. Structural Requirements for Substrates
Ullrich, K. J. (1997) · The Journal of Membrane Biology · doi:10.1007/s002329900247 · Cited by 150
The Clinical Pharmacokinetics of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction
Gupta, M., Kovar, A., & Meibohm, B. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005276847 · Cited by 150
The Use of BDDCS in Classifying the Permeability of Marketed Drugs
Benet, L. Z., Amidon, G. L., Barends, D. M., Lennernäs, H., Polli, J. E., Shah, V. P., Stavchansky, S. A., & Yu, L. X. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9523-x · Cited by 147
Mechanisms and clinical implications of renal drug excretion *
Masereeuw, R., & Rüssel, F. G. M. (2001) · Drug Metabolism Reviews · doi:10.1081/dmr-120000654 · Cited by 142
Drug Interactions and the Cytochrome P450 System
Brøsen, K. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199500291-00005 · Cited by 139
Ziprasidone Metabolism, Aldehyde Oxidase, and Clinical Implications
Beedham, C., Miceli, J. J., & Obach, R. S. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084028.22282.f2 · Cited by 139
Targeting Intestinal Transporters for Optimizing Oral Drug Absorption
Varma, M. V. S., Ambler, C. M., Ullah, M., Rotter, C. J., Sun, H., Litchfield, J., Fenner, K. S., & El‐Kattan, A. F. (2010) · Current Drug Metabolism · doi:10.2174/138920010794328850 · Cited by 138
Self-citationVarma, M. V. S., Lai, Y., Feng, B., Litchfield, J., Goosen, T. C., & Bergman, A. J. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0792-7 · Cited by 136
Self-citationSutton, D., Butler, A. M., Nadin, L., & Murray, M. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36788-6 · Cited by 135
Mazzu, A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110537 · Cited by 135
Yoshida, K. J., Maeda, K., & Sugiyama, Y. (2012) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140309 · Cited by 133
Foti, R., Rock, D. A., Wienkers, L. C., & Wahlstrom, J. L. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032094 · Cited by 132
Åsberg, A., Hartmann, A., Fjeldså, E., Bergan, S., & Holdaas, H. (2001) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2001.10415.x · Cited by 127
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype
KIRCHHEINER, J., THOMAS, S., BAUER, S., TOMALIKSCHARTE, D., HERING, U., DOROSHYENKO, O., JETTER, A., STEHLE, S., TSAHURIDU, M., & MEINEKE, I. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.008 · Cited by 127
Yang, X., Gandhi, Y., Duignan, D. B., & Morris, M. E. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9124-1 · Cited by 126
Zheng, H., Huang, Y., Frassetto, L., & Benet, L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.186 · Cited by 126
Niemi, M., Neuvonen, P. J., Hofmann, U., Backman, J. T., Schwab, M., Lütjohann, D., von Bergmann, K., Eichelbaum, M., & Kivistö, K. T. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200505000-00005 · Cited by 125
Bourdet, D. L., Pritchard, J. B., & Thakker, D. R. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.091223 · Cited by 125
Ménochet, K., Kenworthy, K. E., Houston, J. B., & Galetin, A. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.046193 · Cited by 123
Effect of fluconazole on plasma fluvastatin and pravastatin concentrations
Kantola, T., Backman, J. T., Niemi, M., Kivistö, K. T., & Neuvonen, P. J. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000127 · Cited by 122
STOLTZ, M., REYNOLDS, D., ELKINS, L., SALAZAR, D., & WEIR, S. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90252-x · Cited by 121
Ueo, H., Motohashi, H., Katsura, T., & Inui, K. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.06.024 · Cited by 120
McGinnity, D. F., Parker, A. J., Soars, M., & Riley, R. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15081-7 · Cited by 120
Jeong, H. Y., Choi, S., Song, J., Chen, H., & Fischer, J. H. (2007) · Xenobiotica · doi:10.1080/00498250701744633 · Cited by 117
Renal Tubular Drug Transporters
Launay-Vacher, V., Izzedine, H., Karie, S., Hulot, J. S., Baumelou, A., & Deray, G. (2006) · Nephron Physiology · doi:10.1159/000092212 · Cited by 116
Goodwin, J. T., Conradi, R. A., Ho, N. F. H., & Burton, P. S. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010253i · Cited by 111
Influence of Molecular Structure on Substrate Binding to the Human Organic Cation Transporter, hOCT1
Bednarczyk, D., Ekins, S., Wikel, J. H., & Wright, S. H. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.3.489 · Cited by 111
Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations
Siedlik, P. H., Olson, S. C., Yang, B., & Stern, R. H. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/009127009903900510 · Cited by 110
Jones, H. M., Gardner, I. B., Collard, W. T., Stanley, P. J., Oxley, P., Hosea, N. A., Plowchalk, D., Gernhardt, S., Lin, J., Dickins, M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11539680-000000000-00000 · Cited by 110
Varma, M., Khandavilli, S., Ashokraj, Y., Jain, A., Dhanikula, A., Sood, A., Thomas, N., Pillai, O., Sharma, P., Gandhi, R., et al. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335423 · Cited by 107
Self-citationDi, L., Feng, B., Goosen, T. C., Lai, Y., Steyn, S. J., Varma, M. V. S., & Obach, R. S. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054031 · Cited by 107
Self-citationIn vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin*
Transon, C., Leemann, T., Vogt, N., & Dayer, P. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90054-3 · Cited by 106
Varma, M. V. S., Lai, Y., Kimoto, E., Goosen, T. C., El‐Kattan, A. F., & Kumar, V. S. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0956-5 · Cited by 105
Self-citationFeng, B., LaPerle, J. L., Chang, G., & Varma, M. V. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.482930 · Cited by 105
Self-citationPrediction of Pharmacokinetics and Drug–Drug Interactions When Hepatic Transporters are Involved
Li, R., Barton, H. A., & Varma, M. V. S. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0156-z · Cited by 103
Self-citationPaine, S. W., Ménochet, K., Denton, R., McGinnity, D. F., & Riley, R. J. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037267 · Cited by 102
Jejunal Absorption and Metabolism of R/S-Verapamil in Humans
Sandström, R., Karlsson, A., Knutson, L., & Lennernäs, H. (1998) · Pharmaceutical Research · doi:10.1023/a:1011916329863 · Cited by 101
Müller, F., König, J., Hoier, E., Mandery, K., & Fromm, M. F. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.008 · Cited by 95
The BCS, BDDCS, and Regulatory Guidances
Chen, M.-L., Amidon, G. L., Benet, L. Z., Lennernas, H., & Yu, L. X. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0438-1 · Cited by 93
THE ROLES OF TRANSPORTERS AND ENZYMES IN HEPATIC DRUG PROCESSING
Liu, L., & Pang, K. S. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001149 · Cited by 93
Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism
He, Y., Zhang, W., Chen, Y., Guo, D., Tu, J., Xu, L., Tan, Z., Chen, B., Li, Z., Zhou, G., et al. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.04.003 · Cited by 92
Interplay of Transporters and Enzymes in Drug and Metabolite Processing
Pang, K. S., Maeng, H., & Fan, J. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900258z · Cited by 91
Gupta, R., Gifford, E., Liston, T., Waller, C., Hohman, M., Bunin, B. A., & Ekins, S. (2010) · Drug Metabolism And Disposition · doi:10.1124/dmd.110.034918 · Cited by 91
Organ Clearance Concepts: New Perspectives on Old Principles
Sirianni, G. L., & Pang, K. S. (1997) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1023/a:1025792925854 · Cited by 89
Tomita, Y., Maeda, K., & Sugiyama, Y. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.221 · Cited by 88
El‐Sheikh, A. A. K., Greupink, R., Wortelboer, H. M., van den Heuvel, J. J. M. W., Schreurs, M., Koenderink, J. B., Masereeuw, R., & Rüssel, F. G. M. (2013) · Translational research · doi:10.1016/j.trsl.2013.08.003 · Cited by 87
Structure–activity relationship for human cytochrome P450 substrates and inhibitors
Lewis, D. F. V., Modi, S. P., & Dickins, M. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001391 · Cited by 86
Baneyx, G., Parrott, N. J., Meille, C., Iliadis, A., & Lavé, T. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.002 · Cited by 85
Kalliokoski, A., Backman, J. T., Kurkinen, K. J., Neuvonen, P. J., & Niemi, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.74 · Cited by 84
Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data
Poirier, A., Cascais, A., Funk, C., & Lavé, T. (2009) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-009-9139-3 · Cited by 83
Chu, X.-M., Zhang, L., Wang, G., Zhang, S.-N., Zhou, J.-H., & Hao, H. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1277-7 · Cited by 81
Li, R., Barton, H. A., Yates, P. D., Ghosh, A., Wolford, A. C., Riccardi, K. A., & Maurer, T. S. (2014) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-014-9357-1 · Cited by 79
McDowell, J. A., Chittick, G. E., Stevens, C. P., Edwards, K. D., & Stein, D. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1686-1690.2000 · Cited by 77
INTERACTIONS OF AMOXICILLIN AND CEFACLOR WITH HUMAN RENAL ORGANIC ANION AND PEPTIDE TRANSPORTERS
Li, M., Anderson, G. D., Phillips, B., Kong, W., Shen, D. D., & Wang, J. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006791 · Cited by 77
Prediction of human pharmacokinetics — renal metabolic and excretion clearance
Fagerholm, U. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.11.0002 · Cited by 76
Varma, M. V. S., Chang, G., Lai, Y., Feng, B., El‐Kattan, A. F., Litchfield, J., & Goosen, T. C. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.044628 · Cited by 76
Self-citationCamenisch, G., & Umehara, K. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1784 · Cited by 76
Park, J.-W., Siekmeier, R., Lattke, P., Merz, M., Mix, C., Schuiler, S., & Jaross, W. (2001) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840100600404 · Cited by 74
Kato, Y., Takahara, S., Kato, S., Kubo, Y., Sai, Y., Tamai, I., Yabuuchi, H., & Tsuji, A. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019125 · Cited by 72
Kusuhara, H., & Sugiyama, Y. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903491824 · Cited by 71
Andersson, T. B., Bredberg, E., Ericsson, H., & Sjöberg, H. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.7.715 · Cited by 70
Barton, H. A., Lai, Y., Goosen, T. C., Jones, H. M., El-Kattan, A. F., Gosset, J. R., Lin, J., & Varma, M. V. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.759210 · Cited by 68
Self-citationSubstrate specific metabolism by polymorphic cytochrome P450 2D6 alleles
Bogni, A., Monshouwer, M., Moscone, A., Hidestrand, M., Ingelman‐Sundberg, M., Härtung, T., & Coecke, S. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.04.001 · Cited by 67
Gandhi, Y., & Morris, M. E. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9132-1 · Cited by 66
Lai, Y., Varma, M. V. S., Feng, B., Stephens, J. C., Kimoto, E., El‐Kattan, A. F., Ichikawa, K., Kikkawa, H., Ono, C., Suzuki, A., et al. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.678048 · Cited by 66
Self-citationGreenblatt, D. J., Peters, D. E., Oleson, L. E., Harmatz, J. S., MacNab, M. W., Berkowitz, N. C., Zinny, M. A., & Court, M. H. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03545.x · Cited by 65
Varma, M. V. S., Bi, Y., Kimoto, E., & Lin, J. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.215970 · Cited by 65
Self-citationBiliary secretion of rosuvastatin and bile acids in humans during the absorption phase
Bergman, E., Forsell, P., Åberg, A. T., Persson, E. M., Hedeland, M., Bondesson, U., Knutson, L., & Lennernäs, H. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.04.015 · Cited by 65
In silico Prediction of Total Human Plasma Clearance
Berellini, G., Waters, N. J., & Lombardo, F. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300155y · Cited by 65
Prediction of human pharmacokinetics—biliary and intestinal clearance and enterohepatic circulation
Fagerholm, U. (2008) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.60.5.0001 · Cited by 62
Varma, M. V. S., Lin, J., Bi, Y., Rotter, C. J., Fahmi, O. A., Lam, J. L., El‐Kattan, A. F., Goosen, T. C., & Lai, Y. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.050583 · Cited by 62
Self-citationChau, N., Elliot, D. J., Lewis, B. C., Burns, K., Johnston, M. R., Mackenzie, P. I., & Miners, J. O. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.212258 · Cited by 62
Varma, M. V. S., Scialis, R. J., Lin, J., Bi, Y., Rotter, C. J., Goosen, T. C., & Yang, X. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9614-7 · Cited by 61
Self-citationAmsden, G. W., Kuye, O., & Wei, G. C. G. (2002) · Journal of Clinical Pharmacology · doi:10.1177/0091270002424011 · Cited by 60
Clearance Mechanism Assignment and Total Clearance Prediction in Human Based upon in Silico Models
Lombardo, F., Obach, R. S., Varma, M. V., Stringer, R., & Berellini, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500436v · Cited by 60
Self-citationStereospecific analysis of omeprazole in human plasma as a probe for CYP2C19 phenotype
Kanazawa, H., Okada, A., Higaki, M., Yokota, H., Mashige, F., & Nakahara, K. (2002) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(02)00524-1 · Cited by 58
Shimizu, K., Takashima, T., Yamane, T., Sasaki, M., Kageyama, H., Hashizume, Y., Maeda, K., Sugiyama, Y., Watanabe, Y., & Senda, M. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.01.008 · Cited by 58
Lai, Y. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903127234 · Cited by 57
Biliary excretion in foreign compounds. Sulphonamide drugs in the rat
Millburn, P., Smith, R. L., & Williams, R. T. (1967) · Biochemical Journal · doi:10.1042/bj1051283 · Cited by 55
Benzylpenicillin inhibits the renal excretion of acyclovir by OAT1 and OAT3
Ye, J., Liu, Q., Wang, C., Meng, Q., Sun, H., Peng, J., Ma, X., & Liu, K. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71026-0 · Cited by 55
Yamazaki, M., Kobayashi, K., & Sugiyama, Y. (1996) · Biopharmaceutics & Drug Disposition · doi:10.1002/(sici)1099-081x(199611)17:8<645::aid-bdd986>3.0.co;2-l · Cited by 55
Contribution of Human Hepatic Cytochrome P450 Isoforms to the Metabolism of Psychotropic Drugs
Niwa, T., Shiraga, T., Ishii, I., Kagayama, A., & Takagi, A. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.1711 · Cited by 54
Mück, W. M., Ochmann, K., Rohde, G., Unger, S., & Kuhlmann, J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050408 · Cited by 53
Fenner, K. S., Jones, H. M., Ullah, M., Kempshall, S., Dickins, M., Lai, Y., Morgan, P., & Barton, H. A. (2012) · Xenobiotica · doi:10.3109/00498254.2011.626464 · Cited by 53
The influence of P-glycoprotein on morphine transport in Caco-2 cells. Comparison with paclitaxel
Crowe, A. P. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01366-3 · Cited by 48
Transporter biology in drug approval: Regulatory aspects
Maeda, K., & Sugiyama, Y. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.012 · Cited by 46
Physiologically Based Pharmacokinetic Prediction of Telmisartan in Human
Li, R., Ghosh, A., Maurer, T. S., Kimoto, E., & Barton, H. A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058461 · Cited by 46
Jappar, D., Hu, Y., Keep, R. F., & Smith, D. E. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9726-9 · Cited by 40
In Silico Prediction of Ionization Constants of Drugs
Lee, P. H., Ayyampalayam, S. N., Carreira, L. A., Shalaeva, M. Y., Bhattachar, S., Coselmon, R., Poole, S. K., Gifford, E., & Lombardo, F. (2007) · Molecular Pharmaceutics · doi:10.1021/mp070019+ · Cited by 40
In Silico Classification of Major Clearance Pathways of Drugs with Their Physiochemical Parameters
Kusama, M., Toshimoto, K., Maeda, K., Hirai, Y., Imai, S., Chiba, K., Akiyama, Y., & Sugiyama, Y. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032789 · Cited by 39
In Silico Prediction of Biliary Excretion of Drugs in Rats Based on Physicochemical Properties
Luo, G., Johnson, S. R., Hsueh, M.-M., Zheng, J. J., Cai, H., Xin, B., Chong, S., He, K., & Harper, T. W. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.026260 · Cited by 38
Lewis, D. F. V. (1999) · Experimental and Toxicologic Pathology · doi:10.1016/s0940-2993(99)80024-4 · Cited by 37
Varma, M. V. S., & Panchagnula, R. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20489 · Cited by 35
Self-citationPrediction of Pharmacokinetic Profile of Valsartan in Humans Based on in vitro Uptake‐Transport Data
Poirier, A., Cascais, A., Funk, C., & Lavé, T. (2009) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900116 · Cited by 34
In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery
Feng, B., Varma, M. V., Costales, C., Zhang, H., & Tremaine, L. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.922540 · Cited by 34
Self-citationYamazaki, M., Kobayashi, K., & Sugiyama, Y. (1996) · Biopharmaceutics & Drug Disposition · doi:10.1002/(sici)1099-081x(199610)17:7<607::aid-bdd977>3.0.co;2-l · Cited by 34
MDR1 and OAT1/OAT3 Mediate the Drug-Drug Interaction between Puerarin and Methotrexate
Liu, Q., Wang, C., Meng, Q., Huo, X., Sun, H., Peng, J., Ma, X., Sun, P., & Liu, K. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1235-9 · Cited by 33
The extended clearance model and its use for the interpretation of hepatobiliary elimination data
Camenisch, G., Riede, J., Kunze, A., Huwyler, J., Poller, B., & Umehara, K. (2015) · ADMET & DMPK · doi:10.5599/admet.3.1.144 · Cited by 32
Inhibitory effect of JBP485 on renal excretion of acyclovir by the inhibition of OAT1 and OAT3
Ye, J., Liu, Q., Wang, C., Meng, Q., Peng, J., Sun, H., Kaku, T., & Liu, K. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.06.004 · Cited by 31
Fujino, H., Saito, T., Y. Tsunenari, & Kojima, J. (2004) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2004.20.1-2.25 · Cited by 21
Modelling Human Cytochromes P450 for Evaluating Drug Metabolism: An Update
Lewis, D. F. V. (2000) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2000.16.4.307 · Cited by 20
Narimatsu, S., Nakata, T., Shimizudani, T., Nagaoka, K., Nakura, H., Masuda, K., Katsu, T., Koeda, A., Naito, S., Yamano, S., et al. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.12.014 · Cited by 18
Song, I., Choi, M., Jin, Q., Shim, W., & Shim, C. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0075-0 · Cited by 14
Effects of OCT2 c.602C > T genetic variant on the pharmacokinetics of lamivudine
Choi, C., Bae, J., Keum, S.-K., Lee, Y., Lee, H.-I., Jang, C., & Lee, S. (2012) · Xenobiotica · doi:10.3109/00498254.2012.747710 · Cited by 13
Practical Permeability-Based Hepatic Clearance Classification System (Hepccs) in Drug Discovery
Fan, P. W., Yang, S., Berezhkovskiy, L. M., Cheong, J., Plise, E. G., & Khojasteh, S. C. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.141 · Cited by 7
Research works printed but not linked: 1
- Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, et al. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin Pharmacol. 2014;78:587–98. · DOI · Paper page
Cited by
BDDCS, the Rule of 5 and drugability
Benet, L. Z., Hosey, C. M., Ursu, O., & Oprea, T. I. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.007 · Cited by 892
In vitro to in vivo extrapolation for high throughput prioritization and decision making
Bell, S. M., Chang, X., Wambaugh, J. F., Allen, D. G., Bartels, M., Brouwer, K. L. R., Casey, W. M., Choksi, N., Ferguson, S. S., Fraczkiewicz, G., et al. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.11.016 · Cited by 241
Clearance in Drug Design: Miniperspective
Smith, D. A., Beaumont, K., Maurer, T. S., & Di, L. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01263 · Cited by 177
Prantil-Baun, R., Novak, R., Das, D., Somayaji, M. R., Przekwas, A., & Ingber, D. E. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104748 · Cited by 176
OECD (2021) · OECD series on testing and assessment · doi:10.1787/d0de241f-en · Cited by 174
Metadata
- Authors
- Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F.
- Affiliations
- Pfizer (United States) (US)
- Venue
- Pharmaceutical Research
- Published
- 2015-07-09
- Volume
- 32
- Issue
- 12
- Pages
- 3785-3802
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1894357711
- Cited by
- 334
- References
- 185
- Citations by year
- 2026: 38 · 2025: 35 · 2024: 35 · 2023: 25 · 2022: 34 · 2021: 25 · 2020: 34 · 2019: 32 · 2018: 26 · 2017: 28 · 2016: 19 · 2015: 3
- FWCI
- 26.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Division of Electrical, Communications and Cyber Systems
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- hepatic metabolism, renal clearance, passive membrane permeability, physicochemical properties, MDCK cells, ionization, Biopharmaceutics Classification System, pharmacokinetic variability, drug interactions, pharmacogenomics, drug discovery
- MeSH terms
- Animals, Cell Line, Dogs, Pharmaceutical Preparations, Humans, Kidney, Liver, Metabolic Clearance Rate, Models, Biological, Permeability, Drug Discovery, Renal Elimination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.